From the Journals

Breast cancer: More pathogenic variants detected as multiple-gene sequencing takes over


 

FROM JAMA ONCOLOGY


In previous experience with BRCA1/2 testing, extensive VUS reclassification occurred after broader testing within the population over 2 decades.

“It is a crucial priority to resolve persistent racial/ethnic disparities in genetic information, particularly as increasingly comprehensive sequencing tests enter clinical practice,” the investigators wrote.

Dr. Kurian reported that Stanford University received research funding from Myriad Genetics for an unrelated project. No other conflicts of interest were reported.

SOURCE: Kurian AW et al. JAMA Oncol. 2018 May 10. doi: 10.1001/jamaoncol.2018.0644.

Pages

Recommended Reading

Patient Knowledge of and Barriers to Breast, Colon, and Cervical Cancer Screenings: A Cross-Sectional Survey of TRICARE Beneficiaries (FULL)
Breast Cancer ICYMI
OlympiAD: No statistically significant boost in OS with olaparib in HER2-negative mBC
Breast Cancer ICYMI
Hormone therapy raises diabetes risk in breast cancer survivors
Breast Cancer ICYMI
Early breast cancer: Patients report favorable quality of life after partial breast irradiation
Breast Cancer ICYMI
How does oral contraceptive use affect one’s risk of ovarian, endometrial, breast, and colorectal cancers?
Breast Cancer ICYMI
VIDEO: Office-based hereditary cancer risk testing is doable
Breast Cancer ICYMI
Universal BRCA testing worthwhile for relatives of high-grade serous ovarian cancer patients
Breast Cancer ICYMI
Integrating survivorship care planning in radiation oncology workflow
Breast Cancer ICYMI
Novel targeted cancer drugs cause fewer arrhythmias
Breast Cancer ICYMI
Intravenous antiemetic combination is well tolerated
Breast Cancer ICYMI